Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) went down by -1.61% during the previous trading session, and it is maintaining the win ahead of Wednesday’s trading session. The share price of the Biotechnology giant went up by $1.83 to trade ended Wednesday trading at $1.86. This is down from the $1.86 price recorded on Tuesday’s trading session. Thanks to this latest performance, LXRX is closer to the higher price 52-week target of $9.00 and further from the lowest price target of $2.10. Its performance from the start of the year has also been negative, with LXRX down by -55.90% year-to-date.
Lexicon Pharmaceuticals Inc. (LXRX) started the day trading at $1.89 and recorded an intraday high of $1.9. It also recorded an intraday low of $1.83 during Wednesday’s trading session. Lexicon Pharmaceuticals Inc. is a very active stock that recorded a trading volume that is less than -15.69% of the average daily trading volume on Wednesday. The stock’s trading volume on Wednesday was 811040, which is less than -15.69 of the total average daily trading volume of 938.33K.
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) 2020 Performance Impressive
The increase in LXRX’s stock price on Wednesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of LXRX currently stands at $6.72, which is higher than the current trading price of the stock by 72.77%. However, LXRX’s current trading price is -61.95% lower than the 52-week low price of $1.13. In terms of trading volume, Lexicon Pharmaceuticals Inc. currently experienced healthy participation during the last trading session. 811040 shares of Lexicon Pharmaceuticals Inc. were traded on the stock exchange on Wednesday, which is less than -15.69% of the 938.33K average trading volume of the stock.
The performance of the stock has been positive over the past year. LXRX’s performance over the past one year has seen it plunge by -69.70%, while the stock has gone down by -62.27% in the last six months. The quarterly performance of LXRX currently stands at -19.03%, and it is down by -7.58% in the last month. The only negative figure was from the weekly performance, which currently reads -8.96%. At the time of writing LXRX’s report, the company has a total market cap of $196.80M, making it one of the largest publicly-traded companies in the world.Lexicon Pharmaceuticals Inc. also has over 184 employees all over the world.
LXRX Insider Activities
For Lexicon Pharmaceuticals Inc., insiders hold 99.00% of all company shares. The insider transactions over the past six months are up by 10.10%. During that period, insiders bought 514,090 shares in 46 transactions. In that same period, insiders sold 156,000 of their shares in 14 transactions. After these transactions, insiders at Lexicon Pharmaceuticals Inc. now hold 5.59M shares, which is over 101.48% of the total company stocks. Institutional investors currently hold a large chunk of the LXRX shares, as they control 5.23% of the company’s total stock.
LXRX Fundamental Analysis
For Lexicon Pharmaceuticals Inc., the stock’s diluted earnings per share (EPS) stands at 0.62. In the coming year, analysts expect the EPS to be -0.83. The stock’s EPS growth this year is 197.90%, 23.30% in the previous five years. In terms of revenue, Lexicon Pharmaceuticals Inc.’s quarterly sales (YOY) is shrinking at -0.62, which is lower than the average annual revenue of 23.30% over the past half a decade.
The Return on Investment (ROI) on Lexicon Pharmaceuticals Inc.’s stock currently stands at 40.70%, and it has a net profit margin of 26.60%. The operating margin of the company is 30.10%, and its gross margin is 99.00%.
LXRX Analysts Prediction
The Citigroup has a Neutral rating for Lexicon Pharmaceuticals Inc., predicting the stock price to stay between $3 and $4. Stifel reiterate their Hold position on the stock ($10 and $4)
Analysts at Stifel believe that LXRX is Buy, and they have a price target of between $24 and $23. Stifel and H.C. Wainwright also believe that Lexicon Pharmaceuticals Inc.’s stock is outperforming at the moment.
At the moment, Lexicon Pharmaceuticals Inc.’s Total Debt to Equity ratio stands at 4.47, and they have a long-term Debt to Equity ratio of 4.28.
LXRX Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of LXRX currently stands at -6.83%, while the SMA50 is -6.95%. The biggest one is the SMA200, which is currently reading -37.72% ahead of Wednesday’s trading session. The Relative Strength Index of this stock is 43.21, while its price to earnings ratio (P/E) is 2.98.